Results 111 to 120 of about 178,848,266 (217)
BMC Oral HealthBackground MRONJ (Medication-Related Osteonecrosis of the Jaw) refers to a condition characterized by osteonecrosis of the jawbone associated with the use of certain medications.
Murat Mutlu +2 more
doaj +1 more source
Medication-related osteonecrosis of the jaw (MRONJ): realities, risks and responsibilities
, 2018 Considerable concern and confusion exists about Medication-Related OsteoNecrosis of the Jaw (MRONJ) which can be a painful, prolonged and debilitating condition caused by the death of jaw bone. The most common class of drugs causing this rare problem is
Lakshmi Rasaratnam +2 more
core +1 more source
, 2019 Medication-related osteonecrosis of the Jaw (MRONJ) is an uncommon.
Capodiferro +4 more
core +1 more source
Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis
, 2010 Bisphosphonates are the leading drugs for the treatment of osteoporosis. In randomized controlled trials (RCTs), alendronate, risedronate, and zoledronate have shown to reduce the risk of vertebral, nonvertebral, and hip fractures, whereas RCTs with ...
Graham Russell +8 more
core +1 more source
Ear, Nose & Throat JournalBackground: Antiresorptive drugs are widely used to reduce bone mineral loss in patients with osteoporosis and to prevent skeletal-related events in patients with metastatic cancers and multiple myeloma (MM).
Vojtěch Peřina PhD +2 more
doaj +1 more source
Medication-related osteonecrosis of the jaw : occurence, risk factors, pathogenesis & treatment
, 2019 The antiresorptive drugs bisphosphonates and denosumab are widely used to preserve bone strength by inhibiting osteoclast mediated bone resorption. High dose intravenous bisphosphonates and high dose denosumab are mainly used to treat skeletal related
Hallmer, Fredrik
core
Adjuvant Treatment Options in the Management of Medication-Related Osteonecrosis of the Jaw
, 2015 Osteonecrosis of the jaws is a well-known side-effect of antiresorptive therapy that predominantly occurs in patients suffering from malignant diseases and receiving intravenous administrations of nitrogen-containing bisphosphonates or subcutaneous ...
MANFREDI, Maddalena +2 more
core
How we manage medication-related osteonecrosis of the jaw
European Journal of Medical ResearchBone-modifying agents (BMAs) are integral to managing patients with advanced cancer. They improve quality of survival by reducing skeletal-related events, treating hypercalcaemia and chemotherapy-induced bone loss (Coleman in Clin Cancer Res 12: 6243s ...
H. Byrne +4 more
doaj +1 more source
Risk factors of medication-related osteonecrosis of the jaw – a literature review
Medycyna PaliatywnaMedication-related osteonecrosis of the jaw (MRONJ) is one of the most serious complications of therapy with drugs affecting bone metabolism. This review presents current scientific reports on risk factors for MRONJ and then categorizes them according to
Wojciech Paprotny +3 more
doaj +1 more source
Update on Medication Related Osteonecrosis of the Jaws
Delaware Journal of Public Health, 2023 openaire +2 more sources